<DOC>
	<DOCNO>NCT01255787</DOCNO>
	<brief_summary>The purpose study assess efficacy safety multiple dos vortioxetine , daily ( QD ) , participant major depressive disorder .</brief_summary>
	<brief_title>Efficacy Safety Study Vortioxetine ( Lu AA21004 ) Treatment Major Depressive Disorder</brief_title>
	<detailed_description>The drug test study call vortioxetine . Vortioxetine test treat depression adult major depressive disorder ( MDD ) . This study look MDD relief people take vary dos vortioxetine . The study enrol 600 patient . Participants randomly assign ( chance , like flip coin ) one four treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Vortioxetine 5 mg - Vortioxetine 10 mg - Vortioxetine 20 mg - Placebo ( dummy inactive pill ) - capsule look like study drug active ingredient . All participant ask take one capsule time day throughout study . This multi-center trial conduct 14 country Europe Asia . The overall time participate study 13 week . Participants make weekly visit clinic first 2 week 8-week treatment period every 2 week end 8-week treatment period . Participants complete 8-week treatment period enter 2-week discontinuation period ass potential discontinuation symptom 1 2 week end 8-week treatment period . A safety follow-up contact ( visit phone call ) make 4 week completion 8-week double-blind treatment period ( 2 week end 2-week discontinuation period ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>1 . Suffers Major Depressive Disorder primary diagnosis accord Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR ) criterion ( classification code 296.2x 296.3x ) . 2 . The report duration current major depressive episode least 3 month Screening Visit . 3 . Has MontgomeryÅsberg Depression Rating Scale ( MADRS ) total score ≥26 Screening Baseline Visits . 4 . Has Clinical Global Impression ScaleSeverity ( CGIS ) score ≥4 Screening Baseline Visits . 1 . Has one follow condition : Any current psychiatric disorder Major Depressive Disorder define Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR ; assess Mini International Neuropsychiatric Interview : MINI ) . A participant exhibit symptom anxiety eligible unless fulfil diagnostic criterion current anxiety disorder per DSMIVTR . Current diagnosis history manic hypomanic episode , schizophrenia psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . Current diagnosis history substancerelated disorder ( except nicotine caffeinerelated disorder ) define DSMIVTR . Participant confirm positive urine drug screen ( except prescribe medication medication constitute drug abuse ) exclude . Presence history clinically significant neurological disorder ( include epilepsy ) . Neurodegenerative disorder . ( Alzheimer 's disease , Parkinson 's disease , multiple sclerosis , Huntington 's disease , etc . ) Any DSMIVTR axis II disorder might compromise study . 2 . The current depressive symptom participant consider investigator resistant 2 adequate antidepressant treatment least 6 week duration . 3 . Has receive electroconvulsive , vagal nerve stimulation , repetitive transcranial magnetic stimulation therapy within 6 month prior Screening Visit . 4 . Is currently receive formal cognitive behavioral therapy , systematic psychotherapy , plan initiate therapy study . 5 . Is significant risk suicide score ≥5 Item 10 ( suicidal thought ) MADRS , attempt suicide within 6 month prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Melancholia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>